Company:  VICAL INC (VICL)
Form Type:  8-K
Filing Date:  5/28/2014 
CIK:  0000819050 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.4693 (-25.10%)  
Trade Time: 
02:36 PM EST  
Market Cap: 
Trade VICL now with 

© 2018  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have three active, independent or partnered, development programs in the area of infectious disease comprised of: * An ongoing Phase 3 trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in hematopoietic stem cell transplant, or HCT, recipients in collaboration with Astellas Pharma Inc., or Astellas. Astellas has completed enrollment in the Phase 3 clinical trial and expects top-line data to be available in the first quarter of 2018. * An ongoing Phase 2 trial of VCL-HB01, our Vaxfectin®-formulated therapeutic DNA vaccine for reduction of lesion recurrences caused by herpes simplex virus type 2, or HSV-2, infection.
Register and access this filing in:     
  FORM 8-K
      Item 5.07 Submission of Matters to a Vote of Security Holders.